Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansa Biopharma AB ( (SE:HNSA) ) just unveiled an announcement.
Hansa Biopharma announced successful results from its US Phase 3 ConfIdeS trial for imlifidase, showing significant improvement in kidney function in highly sensitized transplant patients. The positive outcomes, including superior kidney function and dialysis independence, position imlifidase as a potential transformative treatment in kidney transplantation, with plans for a Biologic License Application submission to the FDA by the end of 2025.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, focusing on developing innovative treatments for rare immunological conditions. The company is known for its work in desensitization therapies, particularly in the field of kidney transplantation, with its product imlifidase, marketed under the brand name IDEFIRIX®, conditionally approved in several countries.
Average Trading Volume: 434,958
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.85B
Find detailed analytics on HNSA stock on TipRanks’ Stock Analysis page.